



OPEN Surface markers on supermeres outperform extracellular vesicles in colorectal cancer diagnosis

Sonu Kumar¹, John Alex Sinclair¹, Tiger Shi¹, Gaeun Kim¹, Runyao Zhu¹, Grace Gasper¹, Yichun Wang¹, James N. Higginbotham², Qin Zhang², Dennis K. Jeppesen², Oleg Tutanov², Maxwell Hamilton⁴, Jeffrey L. Franklin^{2,3}, Al Charest^{5,6}, Robert J. Coffey^{2,3}, Satyajyoti Senapati¹✉ & Hsueh-Chia Chang¹✉

Extracellular nanocarriers, such as extracellular vesicles (EVs), lipoproteins, supermeres, and exomeres are diverse lipid-protein-nucleic acid assemblies. Among them, supermeres hold significant diagnostic potential but are challenging to characterize due to limited surface biomarker information and labor-intensive isolation methods. This study introduces an isolation-free Ion Exchange Membrane Sensing method for the detection of supermeres within 30 min using 50 μ L of sample, with a sensitivity of 10^6 – 10^7 supermeres/mL. Validation through ultracentrifugation (UC) and surface plasmon resonance (SPR) confirms the detection accuracy and specificity. Supermeres carry key proteins such as HSPA13, ENO2, and DDR1 analogous to tetraspanin in EV. Supermeres outperform small EVs (sEVs) and exomeres across multiple shared and unique surface proteins critical to colorectal cancer diagnosis, highlighting their superior clinical utility and potential as next-generation biomarkers in precision medicine.

Keywords Anion-exchange membrane, Biosensor, Colorectal cancer, Electrokinetics, Supermeres

Extracellular nanocarriers have emerged as pivotal mediators of intercellular communication and promising biomarkers for a variety of diseases, prompting extensive investigations into their diverse subtypes^{1–8}. This heterogeneous family of nanoparticles comprises classical EVs (Extracellular Vesicles)—including exosomes (30–150 nm, of endosomal origin)^{9,10} and microvesicles (100–1000 nm, derived from the plasma membrane)^{11–14}—as well as other nanoscale entities present in biofluids. Among these are lipoproteins (e.g., HDL [~ 5–12 nm]^{15–17} and LDL [~ 18–28 nm]^{18–20}) and newly identified extracellular nanoparticles that lack a surrounding membrane^{9,21,22}. Notably, exomeres (~ 30–50 nm), recently characterized as non-membranous particles with distinct molecular signatures⁹, and the even smaller supermeres²¹ (~ 15–25 nm), isolated from the supernatant of exomere preparations²², further underscore the complexity of the secretome. These amembranous entities, which do not conform to traditional EV or lipoprotein categories, expand our understanding of cell-secreted particulate diversity^{13,14,23}. Importantly, while classical EVs have been extensively studied^{15,16,24}, supermeres remain underexplored primarily due to the lack of characterization tools and lack of canonical markers, thereby presenting both a challenge and an opportunity for novel biomarker discovery^{21,25–28}.

Supermeres represent a novel class of secreted particles with a unique biochemical composition and potentially significant biological functions^{21,25,26}. Initial studies have demonstrated that supermeres harbor a rich repertoire of proteins and RNAs that are distinct from those found in small EVs or exomeres²¹. Comprehensive proteomic analyses have revealed an abundance of disease-related biomolecules within supermeres, including shed ectodomains of membrane protein fragments and growth factor regulators²¹. For instance, transforming growth factor beta induced (TGFBI) emerged as one of the predominant proteins in supermeres isolated from colorectal cancer models, while other oncogenic elements—such as extracellular fragments of transmembrane proteins like the epidermal growth factor receptor (EGFR)—were similarly enriched²¹. The detection of supermeres in human plasma thus positions them alongside microvesicles, exosomes, and exomeres as promising targets for liquid biopsy diagnostics²⁸. This diagnostic potential is particularly relevant in the era of precision medicine, where the ability to distinguish subtle differences in biomarker profiles can directly impact patient-specific

¹Department of Chemical and Biomolecular Engineering, University of Notre Dame, Notre Dame, IN 46556, USA.

²Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA. ³Department of Cell and Developmental Biology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA. ⁴Program in Cancer Biology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA. ⁵Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. ⁶Cancer Research Institute, Beth Israel Deaconess Medical Center, Boston, MA, USA. ✉email: ssenapat@nd.edu; hchang@nd.edu

therapeutic strategies. However, harnessing their full diagnostic potential necessitates robust isolation and characterization methods, especially given their diminutive size and the overlapping biophysical properties with other nanoparticle fractions in biofluids^{22,25}.

The technical challenges associated with the characterization of supermeres and related extracellular nanoparticle subpopulations are considerable. Although the conventional differential ultracentrifugation technique^{21,22} is effective for enriching these nanoparticles, it requires a large sample volume and days of serial ultracentrifugation steps. Additionally, the particles often co-sediment as heterogeneous mixtures containing other vesicles, protein aggregates, and other nanoparticles^{9,18,29}. This labor-intensive process not only increases the risk of cross-contamination but also compromises the sensitivity and specificity of downstream analyses as these nanoparticles carry overlapping biomarkers^{9,21}. Even with optimized high-speed spins (e.g., 167,000×g for exomeres followed by 367,000×g for supermeres)²², the isolation of supermeres from the contamination by serum proteins and particles of similar dimensions remains challenging. Density gradient ultracentrifugation, using media such as iodixanol or sucrose, has improved purity by more effectively separating vesicles from smaller macromolecular complexes⁹, while techniques like asymmetric flow field-flow fractionation have enabled the initial segregation of exomeres from classical EVs based on differences in hydrodynamic size and density^{30,31}. These technical enhancements are critical not only for a clearer understanding of supermere biology but also for translating these findings into actionable clinical insights. Emerging methodologies, including microfluidic sorting^{32–36} and immunoaffinity capture^{37,38}, have been applied to isolate specific EV subsets; however, these approaches are constrained by limitations such as the need for prior knowledge of inertial properties, precise non-overlapping isoelectric points, specific surface markers, and scalability challenges in clinical settings. Consequently, there remains an unmet need for a selective, user-friendly platform capable of characterizing shared proteins on novel nanoparticles such as supermeres directly within complex biological samples.

To address this gap, we introduce the Ion Exchange Membrane Sensor (IEMS), a novel, charge-gated immunosensor based on permselective membranes that distinguishes supermeres label-free from other extracellular particles by integrating charge-based gating with marker-targeted capture^{15,16,24,39}. We used IEMS with silica nanoparticle labels in our previous studies to characterize exosomes, lipoproteins, and proteins^{15,16,24,39}, unlike the current label-free approach. The IEMS leverages a hydrophilic anion exchange membrane functionalized with antibodies against a selected protein marker, thereby enabling the comprehensive capture of all entities bearing this marker, including supermeres, other nanocarriers, and soluble proteins. It is a charge-based sensor that uses surface charge on the membrane to gate the ion current through the membrane. It employs the electroconvective instability of permselective membranes (in the overlimiting current region) to amplify the current signal of the surface charge. Critically, among nanoparticles, only supermeres as a nanocarrier exhibit a zeta potential of -50 mV (based on our measurements in this work from across multiple sources) that is significantly more negative than the thermal fluctuation threshold ($\sim -R_b T/F = -25$ mV) while remaining substantially larger than soluble proteins and nucleic acids. Hence, the IEMS not only amplifies the signal from the charged supermeres but suppresses noise from the weakly charged interfering proteins in the sample. This unique combination of biophysical characteristics yields a measurable signal exclusively attributable to supermeres even in highly heterogeneous physiological samples like plasma—a selectivity that has been rigorously validated through appropriate control experiments. This sensitivity (10^6 – 10^7 copies/ml limit of detection) and selectivity features of the IEMS enable isolation-free and rapid (< 30 min) supermere detection and quantification in untreated plasma over a 3-log dynamic range, thus overcoming the significant limitations of conventional days-long methods and permitting validation of supermere as a viable biomarker with extensive testing of clinical samples.

Complementary analyses using orthogonal techniques have confirmed that supermeres possess a notably negative charge (approximately -50 mV), attributable to the presence of RNA and an array of surface-accessible proteins—including ENO1, ENO2, HSPA13, DDR1, CEACAM5 (CEA), and TGFB induced (TGFB1)—while classical tetraspanins are undetectable. Importantly, markers such as HSPA13, ENO2, and DDR1 have demonstrated enhanced specificity for supermeres, effectively serving as analogues to tetraspanins in their diagnostic utility. Comparative diagnostic evaluations further revealed that supermeres outperform exomeres and small EVs in detecting colorectal cancer, as evident by a significant differential expression in a cohort of 22 colorectal cancer patients versus 25 healthy controls. Similar trends were observed in additional, albeit smaller, cancer cohorts, with each group exhibiting distinct overexpression profiles. Notably, in two colorectal cancer patients who underwent tumor resection, a marked postoperative decline was observed exclusively in supermere levels—a finding corroborated by ultracentrifugation coupled with surface plasmon resonance analyses. These results further underline the potential of supermere-focused diagnostics to overcome the pitfalls of traditional isolation methods, ultimately supporting more precise clinical decision-making.

Collectively, these findings underscore the potential of supermeres as a novel diagnostic target and highlight the utility of the IEMS platform for rapid, direct characterization of extracellular nanoparticles in clinical biofluids. By integrating a detailed understanding of the biophysical properties of supermeres along with a novel characterization platform, this work highlights supermeres as a promising biomarker class that not only fills a critical gap in our current diagnostic tools but also overcomes the limitations of conventional methodologies.

Results

Size and zeta potential of supermeres, exomeres, and small EVs

We isolated supermeres, exomeres, and small extracellular vesicles (sEVs) pellets from multiple cancer cell-culture media—including a fibroblast control—by differential ultracentrifugation (Fig. 1a) with multiple rounds of pelleting and resuspension to ensure higher purity²². Particle size distributions were determined by dynamic light scattering (DLS), and the surface charge was quantified via electrophoretic light scattering (zeta potential). DLS revealed distinct modal diameters: supermeres (~ 25 nm), exomeres (~ 40 nm), and sEVs ($\sim$




Fig. 1. Characterization of supermeres, exomeres, and small extracellular vesicles (sEVs). **(a)** Schematic of sequential ultracentrifugation-based isolation yielding highly pure fractions of supermeres, exomeres, and sEVs from cell culture media and diverse biofluids. SW32.1Ti and SW60Ti are the rotors used at different steps. **(b)** Dynamic light scattering size distributions demonstrating discrete populations for supermeres (~20–30 nm), exomeres (~30–50 nm), and sEVs (~100–160 nm). **(c)** Zeta potential measurements across multiple cell lines reveal a significantly greater negative surface charge on supermeres compared with exomeres and sEVs. **(d)** Treatment of supermeres with different nucleases significantly reduced their negative zeta potential, confirming surface-associated RNA as the source of high charge. **(e)** Treatment with RNase H-induced zeta potential reduction in supermeres isolated from different cell lines. **(f)** Triton X-100 solubility assays indicate similar detergent sensitivity of supermeres, exomeres, and sEVs. **(g)** Surface plasmon resonance (SPR) quantification of HSPA13-positive supermeres and VCP-positive exomeres relative to CD63-positive sEVs. **(h)** SPR protein profiling highlights unique marker enrichment: HSPA13, DDR1, and ENO2 in supermeres; VCP, FASN, and POTEE in exomeres; CD63, CD81, and EGFR in sEVs; with CEA, DPEP1, GPC1, TGFBI, and ENO1 common to all fractions. **(i)** Immunoprecipitation of HSPA13 from supermere preparations markedly depleted DDR1, ENO2, CEA, GPC1, ENO1, and TGFBI from the supermere fraction but not with immunoprecipitation with isotype control, demonstrating their co-association with HSPA13 and supporting their designation as supermere-specific markers.

100 nm) (Fig. 1b). Although DLS is prone to size overestimation, it reliably distinguishes relative differences in size. The particle peaks differ; however, the overlap among distributions and co-isolated soluble lipoproteins precludes robust size-based characterization alone, especially from plasma with high lipoprotein concentrations.

Furthermore, zeta potential measurements (Fig. 1c) showed that supermeres carry a significantly higher negative surface charge than exomeres or sEVs. The magnitude of the supermere zeta potential (>25 mV) exceeds the thermal noise threshold ($R_b T/F \approx 25$ mV), whereas exomeres and sEVs fall below it. As surface charge density scales exponentially with zeta potential, supermeres possess a net surface charge several orders of magnitude greater than that of exomeres or sEVs. The molecular basis for this elevated charge is examined in subsequent sections. This distinctive electrochemical signature of supermeres carries profound implications for their detection and characterization. The substantially negative zeta potential (approximately −50 mV) positions supermeres in a unique biophysical regime: their surface charge far exceeds the thermal fluctuation threshold, enabling charge-based sensing strategies that are inherently insensitive to weakly charged species such as exomeres, sEVs, and soluble proteins. This property forms the basis for our Ion Exchange Membrane Sensor (IEMS) platform, which exploits the electroconvective instability of permselective membranes to selectively detect and quantify supermeres directly from complex biofluids without prior isolation (Sect. "Direct quantification from complex biofluids in <30 minutes using distinctly different zeta potential of supermeres"). Before describing this detection strategy, we first investigate the molecular origins of this elevated surface charge and examine the protein composition that distinguishes supermeres from other extracellular nanocarriers.

Supermeres carry RNAs on their surface and are solubilized in detergents

To elucidate the origin of the surface charges, supermeres were treated with various nucleases, followed by ultracentrifugation, buffer exchange, and resuspension under uniform initial conditions. These nucleases specifically target different types of nucleic acids, including single-stranded RNA (ssRNA), double-stranded RNA (dsRNA), single-stranded DNA (ssDNA), and double-stranded DNA (dsDNA). As shown in Fig. 1d, nuclease-mediated hydrolysis of surface-bound nucleic acids resulted in a reduction in the magnitude of the zeta potential. Our findings indicate that the negative surface charge on supermeres primarily arises from the presence of RNAs. The change in zeta potential was observed only in supermeres across all tested cell lines, with no effects seen on exomeres or sEVs after RNase H treatment (Fig. 1e). This observation aligns well with a previous report by Zhang et al.²¹, which also suggests RNAs are enriched in supermeres²¹. A more detailed investigation is required to identify the specific type(s) of nucleic acid involved, which we plan to pursue in future studies.

We next assessed detergent solubility using a detergent solubility assay across varying concentrations. Briefly, nanocarrier fractions were treated with varying detergent concentrations, resuspended in phosphate buffer saline (PBS), and subsequently analyzed by surface plasmon resonance (SPR), as illustrated in Fig. 1f. Upon detergent-mediated solubilization of nanocarriers, target proteins bind individually to the SPR surface rather than as part of intact nanocarriers, resulting in decreased SPR signals compared to intact nanocarrier binding. Supermeres showed solubility in Triton X-100 at approximately 0.05–0.1%, based on the SPR signal pre- and post-treatment. This behavior was similar to that of exomeres and sEVs, despite supermeres lacking a clearly defined lipid mono- or bilayer enclosure. The observed solubility of supermeres suggests that detergent molecules, with their hydrophobic and hydrophilic domains, can effectively disrupt the interactions that stabilize supermeres, similar to the behavior observed in exomeres and sEVs. This solubility property further distinguishes supermeres from amyloid-like aggregates, which typically resist detergent solubilization or require substantially higher detergent concentrations.

These findings identify surface-associated RNAs as the source of supermere surface charge and confirm that supermeres are biological assemblies rather than protein aggregates, validating their potential as disease biomarkers.

Protein distribution of supermeres and other nanocarriers

We next examined the protein composition in supermeres, exomeres, and sEVs derived from various cell cultures using SPR, using higher purity nanocarrier fractions (multiple resuspensions/pelleting), specifically targeting major proteins on different nanocarriers, including TGFBI, ENO1, GPC1, CEA (CEACAM5), DPEP1, HSPA13, DDR1, ENO2, FASN, VCP, POTEE, CD9, CD81, CD63, and EGFR. These proteins were selected based on prior studies identifying their prominence and functional relevance within these particle types^{21,22,26}. The SPR data (Fig. 1g, h) indicate that the tetraspanins CD63 and CD81, and EGFR were mostly absent from supermeres and exomeres but highly enriched in sEVs. Conversely, FASN, VCP, and POTEE were primarily associated with exomeres. Proteins HSPA13, DDR1, and ENO2 were specific to supermeres, showing minimal presence in other fractions across different cell culture media. Additionally, TGFBI, ENO1, GPC1, CEA, and DPEP1 appeared significantly across all three fractions. Collectively, the protein distribution results (Fig. 1g, h), supported by DLS and zeta potential findings, substantiate that supermeres represent a distinct nanocarrier population compared to exomeres and sEVs. Also noteworthy is that while HSPA13 + supermeres were expressed significantly relative to CD63 + sEVs for all cell lines studied, they were significantly less abundant in the healthy fibroblast control (Fig. 1g), and this is something that is also shown for healthy human subjects in subsequent sections. Moreover, different proteins seem to be more abundant on supermeres for some cell lines than others. This could potentially pave the way for disease-type detection in our future work, with some limited data shown in a subsequent section with actual human samples.

The SPR data also suggest that HSPA13, DDR1, and ENO2 markers are present on a large percentage of supermeres in a similar way that tetraspanins are found on many EV populations (Fig. 1h). To validate this, we conducted HSPA13 immunoprecipitation on isolated supermere fractions, assessing the coprecipitation of other supermere-associated proteins relative to isotype control (Fig. 1i). The results confirm HSPA13's extensive colocalization with multiple supermere proteins, suggesting that supermeres could potentially be isolated using immunoseparation methods targeting HSPA13, DDR1, or ENO2. However, the significantly lower abundance of these proteins in isolated supermere fractions relative to non-specific proteins, along with the low immunoseparation yields, suggests a high degree of supermere heterogeneity, posing substantial challenges for their characterization. Thus, while immunoseparation is feasible for isolating specific supermere subpopulations based on unique surface proteins, it will be less selective for proteins shared with other nanocarriers, such as CEA, TGFBI, and ENO1. Our objective, therefore, is to develop robust and direct characterization methods capable of efficiently analyzing any supermere subfraction in untreated samples within a practical timeframe, including proteins shared with exomeres and sEVs.

The identification of HSPA13, DDR1, and ENO2 as supermere-enriched markers addresses a critical gap, as supermeres have previously lacked canonical surface proteins analogous to tetraspanins on EVs. Their reduced expression in healthy fibroblast controls relative to sEVs suggests supermere abundance may be disease-associated.

Direct quantification from complex biofluids in < 30 min using distinctly different zeta potential of supermeres

To further characterize supermeres, we utilized a novel Ion Exchange Membrane Sensor (IEMS) platform that distinguishes analytes captured on its surface based on their inherent charge—or the charge on their reporter nanoparticles when a sandwich scheme is employed. This method was previously validated for lipoprotein,

protein, and sEV characterization^{15,16,24,39}; however, for these analytes, a charged silica reporter was necessary due to their negligible native surface charge. It is important to note that, in the cases of lipoproteins, proteins, and sEVs, no significant signal was observed without the charged silica reporter. We exploit this phenomenon to characterize supermeres: by targeting a protein that is shared across different nanocarriers, only supermeres will generate a signal owing to their substantially higher surface charge, while other nanocarriers will not produce a detectable signal.

The IEMS incorporates an anion exchange membrane, which allows the selective passage of anions under an applied electric field. Three distinct regimes characterize the current-voltage behavior of this system: the ohmic regime at lower voltages, the limiting regime at intermediate voltages, and the overlimiting regime at higher voltages^{15,16,24,34,39–43}. At lower voltages, the system follows Ohm's law of the bulk electrolyte, as the voltage drop (resistance) is mostly in the bulk solution, such that the current increases linearly with respect to the voltage. With increasing voltage, the depletion of ions by the permselective membrane creates an ion-depleted region on one side of the membrane whose dimension is roughly that of the sensor (~ 100 microns). Most of the voltage drop now occurs within this small ion-depleted region, and the ion current saturates at a constant asymptote with respect to increasing voltage in this "limiting-current" regime^[44,45]. At even higher voltages, an electroconvective instability introduces convective vortex mixing to replenish ions into the ion-depleted region, thus eliminating the asymptotic limiting current to produce a second rise in the current with respect to the voltage in the overlimiting regime. Without Debye screening under the ion-depleted conditions introduced by the permselective membranes, these transitions, particularly the onset of the electroconvective instability to initiate the overlimiting current, are highly sensitive to the membrane's surface charge, which gates the ion current into the permselective membrane and controls the tangential surface electric field that drives the electroconvective instability^[46,47,48]. The IEMS exploits these surface charge sensitivities of the IEMS to directly characterize highly charged supermeres in biofluids.

Figure 2a presents a schematic of the IEMS platform, while Fig. 2b illustrates a representative current-voltage response. To ensure accurate quantification across experiments, the measured signal was normalized to account for membrane size variations and limiting current (Figure S1, Supporting Information), yielding a charge-based signal in femto Coulombs (fC). Validation with isolated and SPR quantified supermeres from DiFi cell media established a detection limit of approximately 3×10^6 supermeres/mL (~ 5 fM) and sensor saturation at about 10^9 supermeres/mL (~ 10 pM), achieving a dynamic detection range spanning over three orders of magnitude for all surface markers considered (Fig. 2c).

Critically, the platform demonstrated great analytical performance in both spike-in recovery and parallelism assessments. Spike-in recovery experiments, were conducted by adding UC-isolated supermeres from DiFi media into a pooled healthy human plasma sample (our study suggests the healthy human plasma does not carry any significant amount of TGFBI+, CEA + DDR1+, ENO2+, and HSPA13 + supermeres as discussed in next section, see Fig. 3), resulted in nearly 100% recovery across low, mid, and high concentrations within the dynamic range (Fig. 2d). This high recovery rate underscores the assay's accuracy and reproducibility in complex biological matrices. Moreover, when a pooled colorectal cancer (CRC) patient plasma sample was serially diluted with measured signal, as shown in (Fig. 2e) for HSPA13 + supermeres, it was parallel to the standard curve obtained for isolated DiFi supermeres, showing parallelism. The idea behind parallelism is to show that if any inhibitor or interfering species were present in the plasma that interferes with our sensor signal, it gets serially diluted and thus should deviate from being parallel to a standard curve generated using isolated supermeres. The spike-in recovery and parallelism demonstrate the robust and sensitive nature of our platform.

Next, we analyzed DiFi cell media and pooled human plasma samples from colorectal cancer ($n=5$), glioblastoma ($n=5$), and pancreatic adenocarcinoma ($n=5$) samples. We isolated —supermeres, exomeres, sEVs—and a final non-vesicular fraction (filtered to remove entities larger than 300 kDa), nanocarrier fractions using ultracentrifuged material, and subsequently evaluated the signal produced by each antibody-captured supermere under investigation using IEMS. As shown in Fig. 2f–i, the signal was exclusively produced in the supermere fraction and only when the probe specifically targeted a protein that is present on supermeres. For proteins that are shared with other nanocarrier fractions, no signal was detected in any fraction other than supermeres, regardless of whether the source was DiFi media or plasma from different disease groups. Even TGFBI, CEA, and tetraspanins, which are abundant in exomeres/sEVs, do not produce a signal in those fractions, as these nanocarriers are weakly charged and IEMS only produces signals with charged molecules or particles.

Furthermore, to demonstrate that the charge detected by our sensor is indeed co-localized with other proteins on supermeres, we compared untreated supermeres with those treated with RNase H and detergent using both SPR and IEMS. As illustrated in Fig. 2j and k, we observed that SPR produced a signal with both untreated and RNase H-treated supermeres, indicating that the nanocarrier structure remains intact following nuclease treatment. In contrast, IEMS did not produce any signal with RNase H-treated supermeres, as the charge-carrying species on the supermeres had been hydrolyzed. Notably, both SPR and IEMS utilize the same capture probes; hence, both techniques successfully captured the supermeres, but the absence of charge in the RNase H-treated sample prevented IEMS from generating a signal. This outcome confirms the co-localization of the charge with the proteins on supermeres. Additionally, detergent-treated supermeres failed to produce any signal in both SPR and IEMS analyses due to the loss of structural integrity of supermere proteins, as the detergent solubilized the supermeres, thereby eliminating both the protein epitopes and the charge required for detection. It is important to note that among all the treatments, a final buffer exchange was performed to remove any buffer-based effect on SPR results or antibody-antigen kinetics.

Direct characterization from biofluids was demonstrated by characterizing UC-isolated DiFi supermeres with both SPR and IEMS and compared to direct characterization of supermeres without ultracentrifugation using the IEMS, as shown in Fig. 2l – all three methods showed identical results. The concentrations were normalized with respect to TGFBI supermeres to account for any yield bias during ultracentrifugation. Results from all three




Fig. 2. Rapid and direct characterization of supermeres using the Ion Exchange Membrane Sensor (IEMS) (a) Typical schematic of IEMS for supermere characterization with antibodies functionalized on its surface (b) Typical current-voltage curve for IEMS. (c) Calibration plot surface marker-positive supermeres measuring IEMS signal against the known concentration of supermeres (from SPR). (d) Spike-in recovery experiments in healthy plasma show near-complete recovery of DiFi-derived supermeres across low to high concentrations, underscoring the sensor's accuracy and reproducibility in complex biofluids. (e) Parallelism assessment for HSPA13-positive supermeres, wherein a pooled colorectal cancer (CRC) plasma sample is serially diluted and yields a curve parallel to the standard curve generated from isolated DiFi supermeres, indicating minimal matrix interference. (f–i) Comparison of IEMS signals for supermeres, exomeres, small EVs (sEVs), and the non-vesicular fraction (post-filtration) isolated from (f) DiFi cell media or (g) pooled plasma from CRC, (h) glioblastoma GBM, and (i) pancreatic adenocarcinoma PDAC patients. Only supermeres generate a charge-based signal—regardless of marker—while exomeres, sEVs, and the non-vesicular fraction remain undetected. (j,k) Effect of RNase H and detergent on signal of SPR (j) and IEMS (k) showing charge colocalization with surface markers on supermeres. (l) Direct quantification of supermeres from cell media using IEMS, compared to ultracentrifugation (UC) followed by SPR or IEMS, shows excellent agreement across all three methods, validating the rapid (< 30 min) and isolation-free capabilities of the IEMS platform.




Fig. 3. Diagnostic comparison of supermeres, exomeres, and sEVs in colorectal cancer (CRC). The use of different proteins on different nanocarriers in diagnosing a cohort of healthy and colorectal cancer patients. (a) and (b) show the AUC and p-values, respectively, for each of the proteins on different nanocarriers, showing supermeres outperform the other nanocarriers. Supermeres (c–g), Exomeres (h–l), and sEVs (m–q) were characterized with TGFBI (c,h,m), ENO1 (d,i,n), DPEP1 (e,j,o), GPC1 (f,k,p), and CEA (g,l,q).

approaches showed identical outcomes (Fig. 2l), underscoring the sensitivity, robustness, and specificity of the IEMS method, corroborated by the orthogonal SPR technique. More importantly, it underscores that the more than 2 days long characterization with UC + SPR or UC + IEMS produced identical results compared to less than 30 min of characterization using IEMS without any isolation.

This reduces supermere characterization from a 2–3 day process requiring specialized ultracentrifugation to a 30-minute assay using 50 μL of untreated plasma, making clinical translation feasible.

Supermeres demonstrate superior or comparable CRC diagnostic performance to sEVs, while exomeres exhibit limited efficacy via UC + SPR

We next asked whether supermeres offer diagnostic value beyond sEVs and exomeres by comparing all three fractions using identical UC + SPR methodology. Using UC + SPR as a consistent method for characterizing all three nanocarrier fractions—supermeres, exomeres, and sEVs—we evaluated their effectiveness in distinguishing colorectal cancer (CRC) patients from healthy individuals (Fig. 3). We focused on the proteins TGFBI, CEA, ENO1, DPEP1, and GPC1, which are present across all three particle types (Fig. 1h). The spider plots (Fig. 3a, b) demonstrate that supermeres exhibited better or comparable Area Under the Curve (AUC) values and p-values compared to sEVs and notably outperformed exomeres which had weak or no diagnostic potential. While GPC1 showed equivalent diagnostic performance in supermeres and sEVs, supermeres generally provided enhanced diagnostic performance for the remaining proteins. Exomeres, however, demonstrated limited diagnostic capability, with significantly lower discriminative power between CRC patients and healthy individuals. Protein expression levels in healthy controls were markedly higher in sEVs and exomeres, while supermeres were predominantly absent or minimally present (Fig. 3c–q). Furthermore, proteins like GPC1, although abundant in exomeres, offered minimal diagnostic relevance in this fraction.

Subsequently, we analyzed proteins uniquely associated with each UC-isolated nanocarrier type: HSPA13, ENO2, and DDR1 for supermeres; VCP, POTEE, and FASN for exomeres; and CD63, CD81, and EGFR for sEVs. These proteins collectively reflect the overall presence of their respective nanocarriers in plasma. Figure 4a–i




Fig. 4. Comparative analysis of sEV-, exomeres-, and supermere-specific proteins in healthy versus colorectal cancer (CRC) plasma, and their changes following tumor resection. (a–i) Box-and-whisker plots illustrating the plasma concentrations of selected proteins associated with each nanocarrier subtype—small extracellular vesicles (sEVs), exomeres, and supermeres—in healthy controls (left) versus CRC patients (right). Notably, supermere-specific markers as shown in (c), (f), and (i) (DDR1, HSPA13, ENO2) are significantly elevated in CRC patients compared to healthy individuals, whereas exomere- and sEV-specific markers show less pronounced discrimination. (j, k) Concentrations of key proteins on sEVs and (l, m) supermeres in two CRC patients pre- and post-tumor resection. Substantial decreases in supermere-associated proteins are observed post-surgery, whereas sEV-associated proteins exhibit relatively minor changes. These findings underscore the superior diagnostic utility of supermeres over conventional EV markers.

illustrates that supermere-specific proteins were largely absent in healthy controls, whereas exomere- and sEV-specific proteins did not demonstrate significant differences between CRC patients and healthy individuals. Notably, supermeres showed significantly better diagnostic performance based on AUC and p-values for their associated proteins, suggesting a potential direct involvement in cancer pathogenesis. All evaluated supermere-associated proteins showed excellent performance in diagnosing CRC patients, underscoring their clinical potential.

Additionally, we analyzed plasma samples from CRC patients collected before and after tumor resection surgery. Post-surgical samples showed a substantial reduction in supermere-associated proteins, while minimal or negligible changes were observed in the sEV-associated proteins (Fig. 4j–m). These observations highlight the

clinical relevance of supermeres and suggest their potential utility in companion diagnostics, warranting further detailed investigation similar to previously studied sEVs.

The biological implications of these findings are significant. Supermeres were only recently identified as a distinct class of extracellular nanoparticles, and emerging evidence suggests they play active roles in disease processes²⁶. For example, cancer-derived supermeres can transfer aggressive traits such as cetuximab drug resistance and enhanced aerobic glycolysis (Warburg effect) to recipient cells, setting them apart as functional messengers rather than inert carriers. Moreover, supermeres exhibit markedly greater biodistribution and tissue uptake *in vivo* compared to extracellular vesicles, and they harbor a large proportion of extracellular RNA released by tumors, suggesting that tumors shed a prolific number of supermeres loaded with disease-relevant cargo²⁶. This could explain why our readouts for the supermere fraction are so distinct—we are essentially capturing a concentrated stream of tumor-derived information.

By contrast, the sEV and exome fractions contain more “mixed” content (generic vesicle markers or metabolic proteins not exclusively tumor-specific)^{1–8,21}, which may dilute their diagnostic signal relative to supermeres. For example, the fibroblast cell lines secreted significant sEVs and exomeres but not supermeres (Fig. 1h) as well as healthy humans (Fig. 4). These results highlight the value of parsing extracellular particles into subpopulations: by attributing specific biomarkers to their correct carrier (exosome, exomere, or supermere), we can identify which compartment is the richest source of cancer-derived signals. Here, the supermere fraction stands out as a rich and reliable source of cancer biomarkers, many of which were previously unrecognized or conflated within bulk EV analyses.

IEMS rapidly identifies supermeres in healthy vs. CRC diagnosis with similar performance to UC + SPR

Although UC + SPR in the previous section utilized similar characterization methods across different isolated nanocarriers (Figs. 3 and 4), this section focused on IEMS performance in the characterization of supermeres in healthy individuals' vs. CRC patient plasma in less than 30 min. Samples were compared to PDAC (Pancreatic adenocarcinoma, $n = 5$) and GBM (Glioblastoma, $n = 5$) individual human plasma samples. GBM and PDAC samples picked here are different than those used previously in the pooled samples in Fig. 2. We chose HSPA13-positive supermeres due to their abundant nature across cancer types (Fig. 1h), CEA-positive supermeres because CEA is a gastrointestinal-specific marker, and ENO2-positive supermeres because of their abundance in neuronal and gastrointestinal tissues.

Using IEMS, we observe identical performance of HSPA13+, CEA+, and ENO2+ supermeres in healthy vs. CRC, as shown in Fig. 5a–e, respectively, with them performing similarly to their counterparts in Fig. 4 using UC + SPR with similar AUC values. The study shows the variation of surface protein across different diseases, with HSPA13 supermeres abundant across the disease types, parallel to their prevalence across different cell media, but ENO2 supermeres are only abundant in GBM and CRC due to their specific neuronal and gastrointestinal cancer expression. CEA supermeres were mostly only overexpressed in CRC compared to GBM, PDAC, and healthy human subjects, making it most optimal at identifying CRCs. Total CEA in human plasma measured using Enzyme-Linked Immunosorbent Assay (ELISA), on the other hand, was less efficient at differentiating healthy from CRC samples, with an AUC of 0.8575 (Fig. 5e).

Importantly, IEMS also detected small amounts of supermeres in healthy human plasma that were typically missed with SPR due to poor sensitivity of SPR (limit of detection (LOD) $\sim 1\text{e}7$ to $1\text{e}8$ supermeres/mL) compared to IEMS ($< 1\text{e}6$ to $1\text{e}7$ supermeres/mL). Both IEMS and UC + SPR showed a linear trend in concentration above the limit of detection of SPR (Fig. 5d), demonstrating consistency between the orthogonal characterization method and across different surface capture types. The comparable performance between IEMS and UC + SPR confirms that rapid, isolation-free supermere analysis does not sacrifice diagnostic accuracy. Notably, CEA-positive supermeres outperformed total serum CEA, suggesting carrier-specific biomarker measurement may enhance diagnostic sensitivity.

Discussion

Our study identifies and characterizes supermeres as a distinct class of extracellular nanoparticles that exhibit unique biophysical and molecular features compared to classical exosomes and exomeres. Supermeres display a significantly more negative zeta potential—and harbor a specialized protein repertoire, including markers such as HSPA13, ENO2, and DDR1. These features not only distinguish supermeres from other extracellular vesicle subtypes but also underscore their potential as precise and robust biomarkers for cancer diagnostics.

By leveraging the novel Ion Exchange Membrane Sensor (IEMS), we achieved rapid (< 30 min) and sensitive direct quantification of supermeres from complex biofluids made possible by the charge characteristics of supermeres. The IEMS platform effectively overcomes the limitations of conventional isolation methods, demonstrating an extensive dynamic detection range, high recovery, and reproducibility—features validated through parallel assessments with ultracentrifugation coupled with Surface Plasmon Resonance (UC + SPR) that takes over two days for characterization. Notably, our comparative analyses reveal that supermeres provide superior diagnostic performance compared to small extracellular vesicles and exomeres in distinguishing CRC patients from healthy individuals, and the distinct expression profiles of supermere-associated proteins across different cancer types highlight their potential for disease-specific detection.

We acknowledge that our clinical cohort sizes (22 CRC patients, 25 healthy controls, and 5 samples each for GBM and PDAC) are modest and limit statistical power for definitive diagnostic conclusions. However, the strength of this study lies in the direct comparison of supermeres, exomeres, and sEVs using identical sample sets, ensuring that observed differences reflect true biological variation rather than sample heterogeneity. Importantly, the consistent diagnostic performance between the labor-intensive UC + SPR method (requiring > 2 days) and the rapid IEMS platform (< 30 min) validates our approach and demonstrates that methodological




Fig. 5. Rapid IEMS-based detection of supermeres in human plasma outperforms total CEA for colorectal cancer (CRC) diagnosis and correlates with orthogonal methods. **(a–c)** Box plots show significantly elevated concentrations of HSPA13-, CEA-, and ENO2-positive supermeres in CRC patients (pink) compared to healthy controls (blue), with additional data from glioblastoma (GBM, green) and pancreatic adenocarcinoma (PDAC, teal) cohorts. **(d)** Comparison of supermere concentrations measured by Ion Exchange Membrane Sensor (IEMS) versus ultracentrifugation plus Surface Plasmon Resonance (UC + SPR) shows a strong linear correlation across a range of concentrations. **(e)** Total CEA levels in plasma, measured by conventional ELISA, exhibit lower discriminatory power ($AUC = 0.8575$) relative to supermere-based markers **(a–c)**. Box plots represent median, 25th–75th percentile (box), and $1.5\times$ interquartile range (whiskers). Statistical analyses and sample sizes are indicated in the text. These results confirm that IEMS enables rapid (< 30 min), sensitive quantification of supermeres, yielding superior or comparable CRC diagnostic performance to conventional biomarkers and multi-day UC + SPR methods.

shortcuts do not compromise accuracy. Prior to this work, the multi-day isolation requirement for supermere characterization represented a fundamental barrier to large-cohort clinical studies. By reducing characterization time by approximately 100-fold while maintaining diagnostic fidelity, our IEMS platform now makes such studies practical. Future work should expand validation to larger, more diverse cohorts and include conditions that may confound CRC diagnosis, such as inflammatory bowel disease and colorectal polyps, to fully establish disease specificity and incorporate comparison with established clinical markers, including CA19-9, to fully benchmark diagnostic performance.

Experimental section

Ethics statement and human plasma samples

The studies involving human participants were reviewed and approved by the Indiana University Institutional Review Board (#1105005445) and the Institutional Ethics Committee (IEC) at Austin Health, Melbourne, Australia. All methods were performed according to relevant guidelines and regulations. The patients/participants provided written informed consent to participate in the study. All ethical regulations related to human research participants were followed. We obtained the Pancreatic Adenocarcinoma sample from Indiana Biobank, Glioblastoma samples from Andrew Scott and Hui Gan at the Tumour Targeting Laboratory, ONJCRI, Melbourne, Australia, and colorectal cancer and control group samples from Precision for Medicine. An approved IRB protocol is already in place at Precision for Medicine for collecting plasma samples from patients. Precision for Medicine collaborates with regulatory authorities and accrediting organizations worldwide to ensure that the sample collection process and protocol adhere to the latest FDA, EMA, and MHRA guidelines. Samples were stored at -80°C , avoiding multiple freeze-thaw cycles.

Fabrication of ion exchange membrane sensor (IEMS)

An anion-exchange membrane composed of polystyrene–divinylbenzene fine particles with strong basic quaternary ammonium functional groups ($R-(CH_3)_3N^+$), supported by a polyethylene binder and polyamide/polyester textile fiber, was purchased from Mega a.s. (Straz pod Ralskem, Czech Republic) and used as a sensor matrix in this study. Sensors were fabricated by embedding a small membrane piece ($\sim 0.3 \text{ mm} \times 0.9 \text{ mm}$) in epoxy resin (TAP Quik-Cast, Tap Plastics) following a previously reported optimized protocol²⁸. Briefly, the membrane was hand-cut and positioned at the tip of a silicone mold. A glass slide was placed over the top of the membrane piece. A two-component polyurethane epoxy resin (Side A and Side B = 1:1) was applied to embed the IEMS²⁸. A 3D-printed reservoir was then affixed to the membrane disc using the same resin. Fabricated sensors were at least hydrated in deionized (DI) water overnight before use. These membranes were used up to 4 weeks for our experiments. No testing was done for stability of membranes past the 4 week point (<20% batch-to-batch effect on results was observed).

Fabrication of microfluidic biochip

A $25 \text{ mm} \times 54 \text{ mm}$ ($w \times l$) biochip containing a microchannel ($3 \text{ mm} \times 35 \text{ mm} \times 250 \mu\text{m}$, $w \times l \times h$) was constructed using three 0.3-mm-thick polycarbonate sheets using our previously established process²⁸. Sheet layers containing inlet, outlet, channel, and sensor access orifices were cut using a plotter cutter (Graphtec FC700, Japan) and subsequently thermally bonded at 177°C for 15 min (Fisher Scientific Isotemp Oven). Inlet/outlet tubing and three intermediate sensor/electrode mounting ports were attached using Acrifix UV adhesive. Electrode reservoirs were filled with 2% agarose gel to generate a diffusion-restrictive barrier between reservoirs and the microfluidic channel. The chips were reusable as long as stored in a cold humid environment for up to a week at which point old gel was removed and fresh gel was added, with <20% variation observed between different chips.

Antibody functionalization on IEMS

Surface modification and antibody conjugation were performed according to our previously reported protocol²⁸. IEMS surface was first treated with 0.1 M 3,3',4,4'-benzophenonetetracarboxylic acid (Sigma-Aldrich, USA) at pH 7 for 10 min, followed by UV exposure (365 nm, IntelliRay 600 flood lamp) for 90 s while purging with N_2 . Membranes were rinsed with DI water, and the UV activation step was repeated three times to ensure sufficient surface carboxylation²⁸. Modified membranes were then acid-treated in DI water at pH 2 for 5 h, washed with $0.1\times$ PBS, and subsequently activated using EDC (1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide) coupling chemistry. Specifically, 20 μL of 0.4 M EDC in 50 mM pH 6 MES (2-(N-morpholino)ethanesulfonic acid buffer) was incubated on the surface for 40 min, rinsed, and followed by overnight antibody immobilization (0.1 mg/mL) at 4°C ²⁸. These membranes were stable for up to a week when stored in cold, humid conditions. No testing of stability was done past a week. Batch-to-batch variability was <20% in the measurements (variation in the mean of technical replicates in different batches).

Dynamic light scattering and zeta potential measurements

Particle size distributions were measured by dynamic light scattering (DLS) using a Zetasizer Nano ZS (Malvern Panalytical, Malvern, UK) equipped with a 4 mW He-Ne laser ($\lambda = 633 \text{ nm}$) at a backscatter detection angle of 173° . Zeta potential was determined by electrophoretic light scattering using the same instrument with the Smoluchowski approximation.

Ultracentrifugation-based isolation of carrier subpopulations

Ultracentrifugation (UC) considerations

Different papers utilize different rotors that have different sedimentation times. For best UC practice, one should account for the k-factor of the rotor as well as the relative speed to its maximum that is running (k-factor changes with speed). The duration of spin (Time) can be adjusted as follows, between papers in the literature, as well as between different rotors within the same study. The k-factor for SW60 and SW32.1Ti are 45 and 229, respectively, with $g_{\text{rotor, max}}$ of 485,000 g and 187,000 g, respectively.

$$\left[\frac{\text{Time}}{k_{\text{factor}} \times \frac{g_{\text{rotor, max}}}{g_{\text{experiment}}}} \right]_{\text{ROTOR 1}} = \left[\frac{\text{Time}}{k_{\text{factor}} \times \frac{g_{\text{rotor, max}}}{g_{\text{experiment}}}} \right]_{\text{ROTOR 2}}$$

After the nominal time is obtained, some optimization is done if the rotor sizes differ significantly from the ones in the literature, such as between SW60 Ti used in our study and SW32Ti used previously²² for the sEVs. The reported values are the nominal values adjusted such that we find optimal SPR measurements on the distribution of key markers in different fractions.

Small extracellular vesicles (sEVs)

The isolation and quantification of small extracellular vesicles (sEVs) from human plasma and cell media involved a detailed ultracentrifugation protocol. Initially, 200 μL of human plasma is diluted with $1\times$ PBS to a final volume of 1 mL, or 1 mL of concentrated cell media is used directly (concentrated using a 100 kDa filter from 10 mL to 1 mL). This mixture is centrifuged at 12,000 g for 20 min to remove larger particles. The supernatant is then passed through a 220 nm filter to eliminate larger debris. The filtered fluid is added on top of 3 mL of $1\times$ PBS in a 4 mL ultracentrifuge tube and ultracentrifuged at $167,000 \times g$ for 1.5 h using a swinging bucket rotor (Beckman Coulter SW60Ti with k-factor 45), which is preferred for its efficiency in pelleting vesicles compared to fixed angle rotors. After ultracentrifugation, the supernatant is carefully removed, leaving about 0.2 mL to

avoid disturbing the pellet, which is then resuspended in 0.5 mL of ice-cold 1xPBS. For further purification, this resuspended solution is transferred on top of 15.5 mL of 1xPBS in a 17 mL ultracentrifuge tube in SW32.1Ti and ultracentrifuged at 167,000 $\times$ g for 4.5 hours²². This step aims to refine the sEVs by pelleting them again under high-speed centrifugation. After pelleting, the sEVs are resuspended and passed through a 300 kDa filter to remove soluble proteins, thus enhancing the purity of the sEV sample. This additional purification step ensures the isolation of high-quality sEVs, now ready for downstream analyses such as surface plasmon resonance (SPR) to study their composition or concentration. Fig. S2 shows that apolipoproteins are not getting enriched suggesting proper isolation parameters.

Exomeres and supermeres

Exomeres and supermeres particles are isolated from the sEV-isolated supernatant using a previously reported protocol²¹. Briefly, the sEV-isolated supernatant is transferred to a new 4 mL ultracentrifuged tube and centrifuged at 167000 $\times$ g for 6 h in a swinging bucket rotor (Beckman Coulter SW60Ti) to pellet exomeres. The resulting exomere pellet is resuspended in ice-cold 1x PBS and further purified by ultracentrifuging at 167000 $\times$ g in SW32.1Ti for 18 hours²¹. Meanwhile, the supernatant from the exomere spin is ultracentrifuged at 367000 $\times$ g for 24 h to isolate supermere particles in SW60Ti. The resulting supermere pellet is further purified by an additional ultracentrifugation step at 367000 $\times$ g for 24 h in SW60Ti²¹. Finally, both exomere and supermere pellets are resuspended in ice-cold 1x PBS and passed through a 300 kDa filter to remove soluble proteins, thereby further enhancing the purity of the isolated samples.

To convert SPR measurements to actual concentration, we measured the response slope (dR/dt) for each sample and subtracted the blank signal, recorded 30–60 s after injection to avoid optical artifacts. This slope, typically in Response Units per second (RU/s) or pg/mm²·s, reflects the mass accumulation rate on the sensor surface. We then calculated the mass transfer constant (k_m) using the Stokes-Einstein diffusivity ($D = k_B T / 6\pi\eta a$) and the laminar flow equation: $k_m = 0.98 \times (D^2 f / 0.3 h^2 w)^{1/3}$, where we obtained the particle size (a) from NTA, DLS, TEM, or AFM, and the channel dimensions (w , l , h) and flow rate (f) were known parameters. The bulk mass concentration was then calculated as $C_{\text{bulk}} = (1/k_m) \times (dR/dt)$.

To obtain the number-volume density, we estimated the molecular weight from particle size assuming a typical biological density ($\rho \approx 1000$ kg/m³): $MW = N_A \times (\pi/6) \times a^3 \times \rho$. We then derived the particle concentration as $C \approx 2C_{\text{bulk}} / (a^3 \rho)$. To validate this approach, we applied the formula to albumin ($MW = 66.5$ kDa, $a \approx 6$ nm) at 66.5 mg/mL, which yielded approximately 6×10^{17} particles/mL—matching the expected 1 mM concentration to within 5%. We used SI units throughout to ensure consistency.

Surface plasmon resonance-based characterization of isolated sEVs

Prior to use, the SPR system underwent manufacturer-recommended maintenance-chip preparation and was equilibrated in double-distilled water for 12 h. CM5 sensor chips (Series S CM5 SPR chips, Cytiva, Catalog no. 29149603) were primed with 70% glycerol, and the running buffer was exchanged to PBS for 2 h. Antibodies were buffer exchanged and resuspended in 10 mM MES buffer at a pH of 6.0. This solution was flowed over the SPR chip at a rate of 10 μ L/min, delivering 100 μ L of 0.1 mg/mL antibodies for 2 min to ensure appropriate preconcentration behavior. The selected flow channel was then prepared by flowing 1x PBS until a stable baseline was achieved. To functionalize the channel, a coupling solution containing 20 mg each of EDC (1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride, Life Technologies, Catalog no. 22980) and Sulfo-NHS (N-hydroxysulfosuccinimide, Life Technologies, Catalog no. 24510) in 700 μ L of 100 mM MES at pH 4.7 was pushed through the chip for 15 min at the same flow rate. Following this, approximately 400 μ L of the antibody solution (0.1 mg/mL in 10 mM MES pH 6.0) was applied at 10 μ L/min for 25 min. The reaction was quenched by flowing 0.1 M ethanolamine (Life Technologies, Catalog no. 022793.30) for 2 min. The channel was then washed with PBS until a stable baseline was reestablished. The extent of antibody functionalization was assessed by measuring the baseline shift before and after conjugation, with an expected increase of over 2000 response units (RU) indicating successful antibody coupling.

Baseline establishment and experimental conditions for surface plasmon resonance (SPR) measurements were conducted as follows: Initially, the baseline was recorded to ensure stability, defined as a drift rate of less than 0.1 response units (RU) per minute. If the drift exceeded this threshold, the running buffer was flushed overnight or until the baseline stability criteria were met.

Upon achieving a stable baseline, experimental procedures commenced. Two flow rates, 1 μ L/min and 10 μ L/min, were chosen to cover a decade of flow rate variation while minimizing sample volume consumption. At the start of each cycle, the system was first set to a flow rate of 10 μ L/min: the running buffer was flowed for five minutes, followed by a sample injection in high-performance mode for two minutes. Subsequently, the system was washed with the running buffer for 60 s before sequentially injecting Glycine-HCl (10 mM, pH 2) and 1% albumin, each for 20 s. The flow rate was then reduced to 1 μ L/min, and the running buffer was flowed for an additional 30 min, followed by a five-minute sample flow. The flow rate was subsequently restored to 10 μ L/min for the 2 final wash steps and injection sequences identical to the initial set. For both flow rates, the slope of the sensor response between 30 and 120 s post-injection was recorded to assess binding characteristics.

To correct for any system artifacts, a blank cycle was performed immediately following the sample measurements, using phosphate-buffered saline (PBS) instead of the sample to simulate identical injection conditions. The process was identical to that of the sample injections, including the adjustment of flow rates and the sequence of buffer and reagent injections. The measured slopes from the sample and blank cycles were compared to ascertain the specific binding response. These steps were repeated for each new sample, with the resultant signal representing the difference between the slopes obtained during sample and blank measurements, thus providing a corrected and reliable measure of the binding interactions. Based on the mass transfer constant

in a laminar flow, the size of sEVs, the size of the sensor chip, and the diffusivity of sEVs, they are converted to sEV number concentrations.

Cell culture and conditioned media preparation

3D DiFi (CRC) tumor model

DiFi cells, derived from human colorectal carcinoma, were cultured in a three-dimensional (3D) system to replicate the in vivo tumor microenvironment closely. The 3D scaffolds, constructed from type-I collagen at a concentration of 2 mg/mL, were layered in a tripartite structure: basal and top layers of pure collagen flanked a central layer embedding DiFi cells at a density of 5,000 cells/mL. This configuration was incubated at 37 °C in a humidified atmosphere of 5% CO₂²². Culture medium was supplemented with 10% fetal bovine serum (FBS), 2 µg/mL normocin, insulin-transferrin-selenium, epidermal growth factor, hydrocortisone, and T3 thyroid hormone, and refreshed every two to three days.

A375P (Melanoma) & MDA-MB-468 (Breast cancer)

The human melanoma cell line A375P (RRID: CVCL_6233) and the human breast cancer cell line MDA-MB-468 (RRID: CVCL_0419) were maintained in high glucose Dulbecco's Modified Eagle Medium (DMEM, Gibco, USA) enriched with 10% v/v EquaFetal Serum (Atlas Biologicals, USA), 2 mM L-glutamine, 100 U/mL penicillin-streptomycin, and 1 mM sodium pyruvate. These cells were cultured under standard conditions at 37 °C in a 5% CO₂ humidified atmosphere, ensuring optimal growth and maintenance.

Mouse fibroblast 3T3

Mouse fibroblast cells (3T3) were cultured in Minimum Essential Medium (MEM) supplemented with 10% FBS and 1% Antibiotic-Antimycotic Solution. The cells were housed at 37 °C in a humidified 5% CO₂ environment. Passaging involved washing with 1X phosphate-buffered saline (PBS), trypsinization with trypsin-EDTA, and a recovery period of at least one day before experimental use.

SH-SY5Y neuroblastoma

SH-SY5Y human neuroblastoma cells were cultured in Dulbecco's Modified Eagle Medium/Nutrient Mixture F-12 (DMEM/F-12, Gibco) complete medium supplemented with 10% FBS and 1% Antibiotic-Antimycotic Solution at 37 °C in a 5% CO₂ humidified atmosphere.

GBM9 glioblastoma

GBM9 glioblastoma cells were cultured as neurospheres in Neurobasal medium devoid of serum (Gibco) and supplemented with 3 mM GlutaMAX, 1x B-27 supplement, 0.5x N-2 supplement, 20 ng/mL EGF (R&D Systems, MN), 20 ng/mL FGF (PEPROTECH, NJ), and 1% Antibiotic-Antimycotic Solution (Corning). Passaging was performed using the NeuroCult Chemical Dissociation Kit-Mouse (Stemcell Technologies, Canada) following the manufacturer's guidelines.

Data availability

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Received: 21 November 2025; Accepted: 14 January 2026

Published online: 22 January 2026

References

1. Bryja, A. et al. Small extracellular vesicles—A host for advanced bioengineering and Trojan horse of non-coding RNAs. *Life Sci.* **332**, 122126. <https://doi.org/10.1016/j.lfs.2023.122126> (2023). PMID: 37769803.
2. Coumans, F. A. et al. Methodological guidelines to study extracellular vesicles. *Circ. Res.* **120**, 1632–1648. <https://doi.org/10.1161/CIRCRESAHA.117.309417> (2017). PMID: 28495994.
3. Gao, R. & Li, X. Extracellular Vesicles and Pathological Cardiac Hypertrophy. *Adv Exp Med Biol* **1418**, 17–31 (2023). https://doi.org/10.1007/978-981-99-1443-2_2; PMID: 37603270.
4. Gilligan, K. E. R. M. Dwyer. Engineering Exosomes for Cancer Therapy. *Int J Mol Sci* **18**, 1122 (2017). <https://doi.org/10.3390/ijm18061122>; PMID: 28538671.
5. Hagey, D. W. et al. El Andaloussi, extracellular vesicles are the primary source of blood-borne tumour-derived mutant KRAS DNA early in pancreatic cancer. *J. Extracell. Vesicles*. **10**, e12142. <https://doi.org/10.1002/jev2.12142> (2021). PMID: 34595842.
6. Jackson, H. K., Mitoko, C., Linke, F., Macarthur, D. & Kerr, I. D. Coyle. Jackson, extracellular vesicles potentiate Medulloblastoma metastasis in an EMMPRIN and MMP-2 dependent manner. *Cancers (Basel)*. **15**, 2601. <https://doi.org/10.3390/cancers15092601> (2023). PMID: 37174066.
7. Kalluri, R. & LeBleu, V. S. The biology, function, and biomedical applications of exosomes. *Science* **367**, eaau6977. <https://doi.org/10.1126/science.aau6977> (2020). PMID: 32029601.
8. Kottorou, A. et al. Kalofonos. Small extracellular vesicles (sEVs) biogenesis molecular players are associated with clinical outcome of colorectal cancer patients. *Cancers (Basel)*. **15**, 1685. <https://doi.org/10.3390/cancers15061685> (2023). PMID: 36980570.
9. Jeppesen, D. K. et al. Reassessment of Exosome Composition. *Cell* **177**, 428–445 (2019). <https://doi.org/10.1016/j.cell.2019.02.029>; PMID: 30951670.
10. Sabatke, B., Rossi, I. V., Sana, A., Bonato, L. B. & Ramirez, M. I. Extracellular vesicles biogenesis and uptake concepts: A comprehensive guide to studying host-pathogen communication. *Mol Microbiol* **122**, 613–629 (2024). <https://doi.org/10.1111/mmi.15168>; PMID: 37758682.
11. Costa, V. F. D. A. et al. Bertho. Platelet-Derived microvesicles contribute to the pathophysiology of human cutaneous leishmaniasis: A Nano-Flow cytometric approach in plasma samples from patients before and under antimonial treatment. *Microorganisms* **12** <https://doi.org/10.3390/microorganisms12030526> (2024). PMID: 38543577.

12. Lötval, J. et al. C. Thery. Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the International Society for Extracellular Vesicles. *J. Extracell. Vesicles* **3**, 26913 (2014). <https://doi.org/10.3402/jev.v3.26913>; PMID: 25536934.
13. Welsh, J. A. et al. Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches. *J. Extracell. Vesicles* **13**, e12404. <https://doi.org/10.1002/jev2.12404> (2024). PMID: 38326288.
14. Witwer, K. W. et al. Zheng. Updating MISEV: evolving the minimal requirements for studies of extracellular vesicles. *J. Extracell. Vesicles* **10** <https://doi.org/10.1002/jev2.12182> (2021). PMID: 34953156e12182.
15. Kumar, S., Maniya, N., Wang, C., Senapati, S. & Chang, H. C. Quantifying PON1 on HDL with nanoparticle-gated electrokinetic membrane sensor for accurate cardiovascular risk assessment. *Nat. Commun.* **14**, 557. <https://doi.org/10.1038/s41467-023-36258-w> (2023). PMID: 36732521.
16. Kumar, S., Senapati, S. & Chang, H. C. Extracellular vesicle and lipoprotein diagnostics (ExoLP-Dx) with membrane sensor: A robust microfluidic platform to overcome heterogeneity. *Biomicrofluidics* **18**, 041301 (2024). 10.1063/5.0218986; PMID: 39056024.
17. Di Marco, M. et al. A. D. Pino. Triglycerides to high density lipoprotein cholesterol ratio (TG/HDL), but not triglycerides and glucose product (TyG) index, is associated with arterial stiffness in prediabetes. *Diabetes Res Clin Pract* **224**, 112189 (2025). <https://doi.org/10.1016/j.diabres.2025.112189>; PMID: 40252776.
18. Sódar, B. W. et al. Low-density lipoprotein mimics blood plasma-derived exosomes and microvesicles during isolation and detection. *Sci. Rep.* **6**, 24316. <https://doi.org/10.1038/srep24316> (2016).
19. Akkus, E., Oksuz, N. E. & Utkan, G. Low-Density Lipoprotein (LDL) is Associated with Earlier Progression in Synchronous Metastatic Colorectal Cancer Treated without Curative Intent. *J. Gastrointest. Cancer* **56**, 58 (2025). <https://doi.org/10.1007/s12029-025-01166-3>; PMID: 39907838.
20. Nakamura, K. et al. Relationships of the surface charge of Low-Density lipoprotein (LDL) with the serum LDL-Cholesterol and atherosclerosis levels in a Japanese population: the DOSANCO health study. *J. Atheroscler. Thromb.* **32**, 34–47. <https://doi.org/10.5551/jat.64961> (2025). PMID: 38960632.
21. Zhang, Q. et al. Coffey. Supermeres are functional extracellular nanoparticles replete with disease biomarkers and therapeutic targets. *Nat. Cell. Biol.* **23**, 1240–1254. <https://doi.org/10.1038/s41556-021-00805-8> (2021). PMID: 34887515.
22. Zhang, Q., Jeppesen, D. K., Higginbotham, J. N. & Franklin, J. L. Coffey. Comprehensive isolation of extracellular vesicles and nanoparticles. *Nat. Protoc.* **18**, 1462–1487. <https://doi.org/10.1038/s41596-023-00811-0> (2023). PMID: 36914899.
23. Witwer, K. W. et al. Updating the MISEV minimal requirements for extracellular vesicle studies: Building bridges to reproducibility. *J. Extracell. Vesicles* **6**, 1396823. <https://doi.org/10.1080/20013078.2017.1396823> (2017). PMID: 29184626.
24. Maniya, N. H. et al. Chang. An anion exchange membrane sensor detects EGFR and its activity state in plasma CD63 extracellular vesicles from patients with glioblastoma. *Commun. Biology* **7**, 677. <https://doi.org/10.1038/s42003-024-06385-1> (2024).
25. Clancy, J. W., Boomgarden, A. C. & D'Souza-Schorey, C. Profiling and promise of supermeres. *Nat. Cell. Biol.* **23**, 1217–1219. <https://doi.org/10.1038/s41556-021-00808-5> (2021). PMID: 34887514.
26. Jeppesen, D. K., Zhang, Q. & Franklin, J. L. Coffey. Are supermeres a distinct nanoparticle? *J. Extracell. Biol.* **1**, e44. <https://doi.org/10.1002/jex2.44> (2022). PMID: 36311879.
27. Tosar, J., Cayota, A. & Witwer, K. Exomeres and supermeres: monolithic or diverse? *J. Extracell. Biol.* **1**, e45. <https://doi.org/10.1002/jex2.45> (2022). PMID: 36311878.
28. Yu, L. et al. Exomeres and supermeres: Current advances and perspectives. *Bioact. Mater.* **50**, 322–343 (2025). <https://doi.org/10.1016/j.bioactmat.2025.04.012>; PMID: 40276541.
29. Li, J., Zhang, Y., Dong, P. Y., Yang, G. M. & Gurnathan, S. A. A comprehensive review on the composition, biogenesis, purification, and multifunctional role of exosome as delivery vehicles for cancer therapy. *Biomed. Pharmacother.* **165**, 115087 (2023). <https://doi.org/10.1016/j.biopharm.2023.115087>; PMID: 37392659.
30. Zhang, H. & Lyden, D. Asymmetric-flow field-flow fractionation technology for exomere and small extracellular vesicle separation and characterization. *Nat. Protoc.* **14**, 1027–1053. <https://doi.org/10.1038/s41596-019-0126-x> (2019). PMID: 30833697.
31. Petersen, K. E. et al. Gale. A review of exosome separation techniques and characterization of B16-F10 mouse melanoma exosomes with AF4-UV-MALS-DLS-TEM. *Anal. Bioanal. Chem.* **406**, 7855–7866. <https://doi.org/10.1007/s00216-014-8040-0> (2014). PMID: 25084738.
32. Le, M. C. N. & Fan, Z. H. Exosome isolation using nanostructures and microfluidic devices. *Biomed. Mater.* **16**, 022005. <https://doi.org/10.1088/1748-605X/abde70> (2021). PMID: 33477118.
33. Li, Z. et al. Surface-modified mesoporous nanofibers for microfluidic immunosensor with an ultra-sensitivity and high signal-to-noise ratio. *Biosens. Bioelectron.* **166**, 112444 (2020). <https://doi.org/10.1016/j.bios.2020.112444>; PMID: 32758910.
34. Taller, D. et al. On-chip surface acoustic wave lysis and ion-exchange nanomembrane detection of Exosomal RNA for pancreatic cancer study and diagnosis. *Lab. Chip.* **15**, 1656–1666. <https://doi.org/10.1039/C5LC00036J> (2015).
35. Tayebi, M., Zhou, Y., Tripathi, P., Chandramohanadas, R. & Ai, Y. Exosome purification and analysis using a facile microfluidic hydrodynamic trapping device. *Anal. Chem.* **92**, 10733–10742. <https://doi.org/10.1021/acs.analchem.0c02006> (2020). PMID: 32613828.
36. Sharma, H., Yadav, V., D'Souza-Schorey, C., Go, D. B. & Senapati, S. Chang. A scalable High-Throughput isoelectric fractionation platform for extracellular nanocarriers: comprehensive and Bias-Free isolation of ribonucleoproteins from Plasma, Urine, and saliva. *ACS Nano* **17**, 9388–9404. <https://doi.org/10.1021/acsnano.3c01340> (2023). PMID: 37071723.
37. Klingeborn, M., Skiba, N. P., Stamer, W. D. & Bowes Rickman, C. Isolation of retinal exosome biomarkers from blood by targeted immunocapture. *Adv. Exp. Med. Biol.* **1185**, 21–25. https://doi.org/10.1007/978-3-030-27378-1_4 (2019). PMID: 31884583.
38. Pfeiffer, A. et al. Selective immunocapture reveals neoplastic human mast cells secrete distinct microvesicle- and exosome-like populations of KIT-containing extracellular vesicles. *J. Extracell. Vesicles* **11**, e12272. <https://doi.org/10.1002/jev2.12272> (2022). PMID: 36239715.
39. Ramshani, Z. et al. A multiplexed immuno-sensor for on-line and automated monitoring of tissue culture protein biomarkers. *Talanta* **225**, 122021. <https://doi.org/10.1016/j.talanta.2020.122021> (2021). PMID: 33592751.
40. McCarthy, K. P., Go, D. B., Senapati, S. & Chang, H. C. An integrated ion-exchange membrane-based microfluidic device for irreversible dissociation and quantification of MiRNA from ribonucleoproteins. *Lab. Chip.* **23**, 285–294. <https://doi.org/10.1039/d2lc00517d> (2023). PMID: 36524732.
41. Ren, X. et al. Zorlutuna. A multiplexed ion-exchange membrane-based MiRNA (MIX.miR) detection platform for rapid diagnosis of myocardial infarction. *Lab. Chip.* **21**, 3876–3887. <https://doi.org/10.1039/d1lc00685a> (2021). PMID: 34546237.
42. Ren, X. et al. Towards real-time myocardial infarction diagnosis: a convergence of machine learning and ion-exchange membrane technologies leveraging MiRNA signatures. *Lab. Chip.* **24**, 5203–5214. <https://doi.org/10.1039/d4lc00640b> (2024). PMID: 39415669.
43. Senapati, S. et al. An ion-exchange nanomembrane sensor for detection of nucleic acids using a surface charge inversion phenomenon. *Biosens. Bioelectron.* **60**, 92–100 (2014). <https://doi.org/10.1016/j.bios.2014.04.008>; PMID: 24787123.
44. V. G. Levich. Physicochemical Hydrodynamics. (Prentice-Hall, Englewood Cliffs, NJ, 1962).
45. Chang, H. C. & Yeo, L. Y. *Electrokinetically Driven Microfluidics and Nanofluidics* (Cambridge University Press, 2010).
46. Yossifon, G., Mushenheim, P., Chang, Y. C. & Chang, H. C. Eliminating the limiting-current phenomenon by geometric field focusing into nanopores and nanoslots. *Physical Review E—Statistical, Nonlinear, and Soft Matter Physics*, **81**, 046301 (2010). <https://doi.org/10.1103/PhysRevE.81.046301>; PMID: 19113713.

47. Yossifon, G. & Chang, H. C. Selection of nonequilibrium overlimiting currents: universal depletion layer formation dynamics and vortex instability. *Phys. Rev. Lett.* **101**, 254501. <https://doi.org/10.1103/PhysRevLett.101.254501> (2008). PMID: 19113713.
48. Sensale, S., Ramshani, Z., Senapati, S. & Chang, H. C. Universal features of non-equilibrium ionic currents through perm-selective membranes: gating by charged nanoparticles/macromolecules for robust biosensing applications. *J. Phys. Chem. B.* **125**, 1906–1915. <https://doi.org/10.1021/acs.jpcc.0c09916> (2001). PMID: 33410691.

Acknowledgements

We would like to thank Prof. Crislyn D'Souza-Schorey, Department of Biological Sciences, University of Notre Dame, for providing the melanoma cell line media samples, and Andrew M. Scott and Hui K. Gan, Tumour Targeting Laboratory, ONJCRI, Melbourne, Australia, for providing the Glioblastoma patient samples. We would also like to thank the Notre Dame Biophysics Instrumentation Core Facility for the use of the Biacore T200 SPR system, which was purchased with funding from the NIH (S10 OD028553).

Author contributions

S.K., S.S., and H.C.C. conceived the idea; S.K., J.A.S., and T.S. acquired all data; S.K., S.S., H.C.C., J.L.F., and R.J.C. performed formal analysis; S.S. and H.C.C. acquired the funding and organized the project; S.K. and S.S. designed the experiments; S.K. conducted all IEMS experiments and characterization, including clinical samples in blind; S.K., G.G., and S.S. fabricated the sensor, microfluidic chip, and functionalized the sensor; S.K. and J.A.S. functionalized the SPR chip and performed the SPR experiments; S.K. and T.S. performed the ELISA experiments; G.K. and R.Z. provided the breast cancer, Neuroblastoma, and fibroblast cell lines; J.N.H., Q.Z., D.K.J., O. T., and M.X. provided the DiFi cell lines and purified DiFi EVs, supermeres, and exomeres samples; S.K. developed the figures and drafted the original manuscript. S.S., H.C.C., Y.Z., J.L.F., Q.Z., A.C., and R.J.C. reviewed and edited the manuscript with input from all authors.

Funding

This work was partially supported by the NIH Commons Fund, through the Office of Strategic Coordination/Office of NIH Director, 1UH3CA241684-01 (HCC & SS). R.J.C. acknowledges R35CA197570 and P50CA236733 from the National Cancer Institute, as well as the generous support from the Nicholas Tierney Memorial GI Cancer Fund.

Declarations

Competing interests

The authors declare no competing interests.

Additional information

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1038/s41598-026-36626-8>.

Correspondence and requests for materials should be addressed to S.S. or H.-C.C.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2026